LENZ
LENZ Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$304.45M
P/E Ratio
—
EPS
$-2.85
Beta
2.29
52W High
$50.40
52W Low
$8.25
50-Day MA
$12.85
200-Day MA
$26.72
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About LENZ Therapeutics Inc
LENZ Therapeutics Inc is an innovative biopharmaceutical company dedicated to developing breakthrough therapies for neurological disorders, addressing significant unmet medical needs in the central nervous system (CNS). Utilizing advanced research in drug formulation and delivery, LENZ aims to enhance patient outcomes through its proprietary technologies and a robust product pipeline. The company’s strategic partnerships and commitment to rigorous clinical research underscore its potential as a key player in the biopharmaceutical industry, positioning it for considerable growth and influence in the evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | $19.09M |
| Gross Profit (TTM) | $18.67M |
| EBITDA | $-90.85M |
| Operating Margin | -2422.00% |
| Return on Equity | -33.60% |
| Return on Assets | -21.90% |
| Revenue/Share (TTM) | $0.66 |
| Book Value | $9.07 |
| Price-to-Book | 1.07 |
| Price-to-Sales (TTM) | 15.95 |
| EV/Revenue | 0.611 |
| EV/EBITDA | -7.99 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $31.35M |
| Float | $20.08M |
| % Insiders | 2.65% |
| % Institutions | 115.96% |
Analyst Ratings
Consensus ($41.14 target)
1
Strong Buy6
BuyData last updated: 4/8/2026